Pharmaceutical/Health Care

There is no doubt that Japan’s pharma industry, already having undergone a series of big ticket mergers  in recent years, is about to undergo further dramatic changes. As Japan’s population continues to age and health care costs and the burden on Government expenditure increases, the industry is confronting pressures from a number of sources.
An analyst's report from Fukoku Mutual Life Insurance, sees a number of key issues: